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AntimicrobialAbstract A simple and efﬁcient methodology was developed for the synthesis of new 4-(3,
5-dimethyl-1-phenyl-1H-pyrazol-4-ylazo)-N-(2-substituted-4-oxo-4H-quinazolin-3-yl)benzenesul-
fonamide derivatives 10a–10j in good amount of yields. They have been prepared using 2-acetam-
idobenzoic acid derivatives 2a–2j via intermediates benzenesulfonamide substituted
quinazolinone derivatives 8a–8j, and its corresponding hydrazono derivatives 9a–9j. Entitled
compounds (10a–10j) were also obtained using microwave heating in good amount of yields.
The structures of all the new compounds have been evaluated on the basis of elemental analysis,
FT-IR, 1H and 13C NMR spectral studies. Entitle compounds have been screened for their in vitro
antimicrobial activities and all these compounds displayed excellent to moderate activities, which
were found to be signiﬁcantly potent against bacteria compared to fungal.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Perusal of literature survey reveals that the quinazolinone skel-
eton is found in a number of biologically active molecules.
There are various reports regarding substitution at 2nd and/
or 3rd position of quinazolinone skeleton. Speciﬁcally,
4(3H)-quinazolinone derivatives display a broad range of
S30 N.A. Sojitra et al.biological properties such as antihypertensive (Haruhisa et al.,
2006), CNS depressant (Kashaw et al., 2009; Saber et al.,
2007), antitumor, analgesic and anti-inﬂammatory, antibacte-
rial and antifungal activities (Pandey et al., 2009; Laddha
et al., 2006; Sondhi et al., 2010). Octahydroquinazolinone
derivatives have exhibited potent antibacterial activity against
Staphylococcus aureus, Escherichia coli, Pseudomonas aerugin-
osa (Kidwai et al., 2005) and calcium antagonist activity
(Yarim et al., 2002, 2003; Kantevari et al., 2006). These classes
of compounds have also shown interference with insulin secre-
tion and smooth muscle contractile channel activity (Somers
et al., 2001). On the other hand, various therapeutic activities
have also been reported for the pyrazole moieties (Hong et al.,
2009; Badawey and El-Ashmawey, 1998; Bailey et al., 1985).
However, there are no such reports in which both quinazoli-
none and pyrazole rings are linked by benzenesulfonamide
substituted hydrazono bridge. Therefore, it was thought inter-
esting to bring the above two moieties within a single molecu-
lar framework to afford their additive biological properties.
Thus, the present communication comprises synthesis, charac-
terization and antimicrobial activities of newer 4-(3,5-dimethyl
-1-phenyl-1H-pyrazol-4-ylazo)-N-(2-substituted-4-oxo-4H-
quinazolin-3-yl)benzenesulfonamide derivatives 10a–10j.2. Results and discussion
2.1. Chemistry
Majority of the reported 4(3H)-quinazolinone derivatives were
synthesized either from anthranilic acid or its derivatives
(Hisano, 1973) (shown in Scheme 1). There are very few
reports (Zahran, 2000; Gupta et al., 1988; Morsy, 2007)
regarding preparation of the compound 6a, expect our recently
reported work [8a–8j] (Jagani et al., 2011). The reported meth-
ods for the synthesis of compound 6a involve the sulfonylation
of 3-aminoquinazolinone (4) using p-acetamidobenzenesulfo-
nylchloride (5) under reﬂux condition in the presence of base
(i.e. pyridine or NaOH) as shown in Scheme 1 (yields were
in the range of 58 to 66%). In another report (Yuefen et al.,
2004), compound 6a was prepared using 2-methyl-4H-3,1-Scheme 1 General routes of syntbenzoxazin-4-one (3) and N-[4-(hydrazinosulfonyl)phenyl]
acetamide (7) as shown in Scheme 1.
The above methods proceed via highly moisture sensitive,
irritant, and electronically unsaturated character of unstable
2-methyl-4H-3,1-benzoxazin-4-one (3) bearing substitution at
second position which renders them difﬁcult to synthesize
(Madkour, 2005). In addition to this, more number of syn-
thetic steps decreases the overall yield.
To overcome such problems, we have established the reac-
tion pathway for the synthesis of 4-amino-N-(2-methyl-4-oxo-
quinazolin-3(4H)-yl)benzenesulfonamide 8a and its derivatives
(8a–8j) (Jagani et al., 2011), which was again optimized by
changing reaction conditions to prepare the same compounds
and is shown in Scheme 2. The structure of compounds 8a–8j
was conﬁrmed by mass spectra and melting point.
4-[N0-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(2-methyl-
4-oxo-4H-quinazolin-3-yl)benzenesulfonamide derivatives 9a–
9j were prepared starting from 4-amino-N-(2-methyl-4-oxoqui-
nazolin-3(4H)-yl)benzenesulfonamide 8a–8j, and is shown in
Scheme 3.
Pyrazole derivatives (10a–10j) were prepared via both clas-
sical and microwave irradiation from hydrazono compounds
(9a–9j), as shown in Scheme 3. Comparisons of both synthetic
approaches have been displayed in Table 1, which showed
optimization of reaction time and an increase in yields under
microwave condition.
The structure of compounds 9a–9j was conﬁrmed by IR, 1H
NMR, 13C NMR, and mass spectra and the characterization
of 9a is included herewith (Pavia et al., 2008). The IR spectrum
of 9a showed the presence of C‚O group at 1695 cm1 due to
CONH and COCH3 groups. Two sharp bands at 1324 and
1142 cm1 were due to asymmetric and symmetric stretching
vibrations of SO2 group, respectively. The two bands at 1510
and 1550 cm1 were due to NAH bending of secondary amine
and sulfonamide groups respectively. The 1H NMR of 9a
showed a singlet at d 10.91 ppm due to highly deshielded pro-
ton of NHSO2 group. One singlet was observed at d 9.11 ppm
due to secondary amine group. The two more singlets
appeared in the aliphatic region at d 2.51 and 2.25 ppm due
to COCH3 and CH3 protons at second position of the quinaz-
olinone ring respectively. All the 8 aromatic protons resonatedhesis of quinazolin-4(3H)-one.
Table 1 Comparison of time consumed and yield obtained under conventional and microwave heating.
S. No. Substitution Conventional heating Microwave heating
R R1 R2 Time (h) Yield (%) Time (min.) Yield (%) Power (watt)
10a CH3 H H 6.5 73 5.0 78 210
10b CH3 Br H 7.0 76 5.5 82 210
10c CH3 Br Br 7.5 83 6.0 88 245
10d C6H5 NO2 H 6.0 78 5.0 79 245
10e C6H5 H H 5.5 81 4.5 84 210
10f C6H5 Br H 6.0 71 5.0 77 210
10g C6H5 Br Br 7.5 78 6.0 83 245
10h 4-ClAC6H4 H H 7.0 73 6.5 76 245
10i 4-ClAC6H4 Br H 6.5 78 5.5 86 245
10j 4-ClAC6H4 Br Br 6.5 73 6.0 84 245
Scheme 3 Proposed synthetic route for hydrazono 9a–9j and pyrazole 10a–10j derivatives of quinazolin-4(3H)-one.
Scheme 2 Proposed synthetic route for the synthesis of p-aminobenzenesulfonamide substituted quinazolin-4(3H)-one 8a–8j.
Classical and microwave assisted synthesis S31in the region of d 7.75–6.63 ppm. The 13C NMR of 9a showed
two signals of carbonyls carbon at d 190.0 ppm (COCH3) and
188.1 ppm (CO of quinazolinone). The aromatic carbons ap-
peared at d 158.6, 153.1, 146.5, 135.4, 130.2, 127.5, 127.1,
126.8, 123.7, 121.0, and 113.0 ppm. Signals due to remaining
two quaternary carbons appeared at d 157.3 ppm
(N‚CACH3) and 130.25 ppm (COACACO). The signals
due to aliphatic carbons appeared at 28.8 ppm (COCH3) and
23.1 ppm (CH3). The molecular ion peak (m/z) was observed
at 442.2 in the mass spectrum of 9a for molecular formula
C20H19N5O5S. Similarly, the data for compounds 9a–9j are gi-
ven in the experimental section.
4-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylazo)-N-(2-sub
stituted-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide deriva-
tives 10a–10j were prepared from 4-[N0-(1-acetyl-2-oxo-propyl-
idene)hydrazino]-N-(2-methyl-4-oxo-4H-quinazolin-3-yl)
benzenesulfonamide derivatives 9a–9j by cyclization in the
presence of phenyl hydrazine and is shown in Scheme 3. The
structures of compounds 10a–10j were conﬁrmed by IR, 1H
NMR, 13C NMR, and mass spectra and are described in theexperimental section. The data of compound 10a were com-
pared with the data of compound 9a. The IR spectrum of
10a showed the band at 1698 cm1 due to the presence of
C‚O group of quinazolinone ring (Pavia et al., 2008;
Mikhailovskii and Shklyaev, 1992), the band at 1510 cm1
due to NAH bending of secondary amine in compound 9a dis-
appeared in compound 10a due to cyclization and a new band
appeared at 1580 cm1 due to N‚N stretching. The bands due
to NHSO2 and C‚O groups were not much affected. In con-
trast to the 1H NMR spectrum of compound 9a, in the 1H
NMR spectrum of compound 10a, the NH proton singlet at
d 9.11 ppm and the COCH3 protons at d 2.51 ppm of 9a disap-
peared due to the formation of pyrazole ring. The 13C NMR of
10a showed the signal of carbonyl carbon at d 158.3 ppm due
to CO group of quinazolinone ring. The aromatic carbons ap-
peared at d 151.9, 146.8, 146.1, 144.0, 139.1, 135.4, 128.6,
127.1, 126.8, 126.0, 123.7, 121.0, 119.6, and 113.0 ppm. Sig-
nals due to remaining two quaternary carbons appeared at d
156.5 ppm for N‚CACH3 in quinazolinone ring and
130.2 ppm for carbon of pyrazole ring (CACACH3). In the
Table 2 Antimicrobial activity of the synthesized compounds.
Compound Minimum Inhibitory Concentration lg/mL
Gram positive bacteria Gram negative bacteria Fungal
S. aureus B. subtilis E. coli P. aeruginosa A. niger A. clavatus
9a 25 200 50 150 200 250
9b 100 200 200 200 200 250
9c 200 100 150 250 250 250
9d 50 100 200 50 250 200
9e 250 150 250 250 >200 250
9f 100 200 100 200 200 250
9g 150 250 250 25 >200 250
9h 200 25 200 200 200 200
9i 150 200 25 50 200 250
9j 200 200 200 150 200 250
10a 25 250 200 100 200 250
10b <100 50 200 200 200 250
10c 150 25 200 250 >200 250
10d 200 100 150 200 250 250
10e 250 250 100 100 250 >200
10f 100 200 200 150 250 200
10g 25 200 250 250 >200 250
10h 50 150 150 200 200 250
10i 100 200 >250 150 >200 250
10j 150 >250 100 100 250 250
Streptomycin 10 10 10 10 – –
Nystatin – – – – 50 50
S32 N.A. Sojitra et al.downﬁeld region the signal appeared at 22.5 ppm due to the
methyl groups at second position of the quinazolinone ring
and two signals at 12.2 and 10.3 ppm due to pyrazole ring.
The molecular ion peak (m/z) appeared at 514.2 in the mass
spectrum of 10a for molecular formula C26H23N7O3S.
2.2. Evaluation of in vitro antimicrobial activity
The in vitro antimicrobial activities of the synthesized com-
pounds 9a–9j and 10a–10j have been investigated against the
bacterial species S. aureus (ATCC 25923), Bacillus subtilis
(ATCC 11774), E. coli (ATCC 25922) and P. aeruginosa
(ATCC 25619), whereas of fungal species Aspergillus niger
(ATCC 64958) and Aspergillus clavatus (ATCC 66027). The
antibacterial and antifungal activities have been performed
using the serial broth dilution method (Jani et al., 2010;
Thangadurai and Natarajan, 2001). The minimum inhibitory
concentration (MIC) values of the compounds are summarized
in Table 2.
The antibacterial evaluation of the synthesized compounds
revealed that among all the compounds 9a, 9d, 10a, 10c, 10g
and 10h showed excellent activity against Gram positive B.
subtilis, whereas compounds 9h, 10b and 10c showed good
activity against S. aureus. Similarly compounds 9a and 9i
showed excellent results against Gram negative bacterial spe-
cies E. coli, while compounds 9d, 9g and 9i showed good activ-
ity against P. aeruginosa. Compound 10e was poor against B.
subtilis. While remaining compounds were moderately or
slightly active against Gram-positive and Gram-negative bac-
teria species. In vitro antimicrobial activities and all these com-
pounds displayed excellent to moderate activity, which were
found to be signiﬁcantly potent against bacteria as compared
to fungal.3. Experimental
3.1. Material and measurements
All reagents were of analytical reagent (AR) grade purchased
commercially from Spectro chem. Ltd., Mumbai, India and
used without further puriﬁcation. Solvents employed were
distilled, puriﬁed and dried by standard procedures prior to
use (Jeffery, 1989). All reactions were monitored by thin-layer
chromatography (TLC on aluminum plates coated with silica
gel 60 F254, 0.25 mm thickness, E. Merck, Mumbai, India)
and detection of the components were measured under UV
light or explored in Iodine chamber. Carbon, hydrogen
and nitrogen elemental analyses were estimated by a
PerkinElmer 2400-II CHN elemental analyzer, USA. 1H and
13C NMR measurements were carried out on a Bruker
Advance-II 400 MHz NMR spectrometer. The chemical shifts
were measured with respect to TMS which was used as an
internal standard and DMSO-d6 used as solvent. Infrared
spectra of compounds were recorded in the region of 4000–
400 cm1 on a Shimadzu 8501 Fourier-Transform Infrared
Spectrophotometer using KBr pellets. Mass spectra were
scanned on a Shimadzu LCMS 2010 spectrometer. Melting
point of the compounds was measured by the open capillary
tube method.3.2. General procedure for the preparation of 3-sulfonamide
substituted quinazolinone derivatives 8a–8j
In a three-necked, 500 mL, round bottom ﬂask equipped with
a mechanical stirrer, reﬂux condenser, pressure equalizer fun-
nel were placed N-[5-(hydrazinosulfonyl)phenyl]acetamide 7
Classical and microwave assisted synthesis S33(0.1 mol) and 2-acetamidobenzoic acid derivatives 2a–2j
(0.1 mol) which were prepared by the reported method
(Friedman et al., 1960; Jeffery et al., 1989) and 175 mL of tol-
uene. The mixture was stirred well and treated drop-wise with
a solution of phosphorus trichloride (0.0335 mol) in 25 mL of
toluene over a period of 15 min. The resulting suspension was
reﬂuxed in oil-bath at 130 C for 2–3 h. The progress of
reaction was monitored by TLC (9:1, CHCl3:CH3OH sol-
vent system). The solvent was removed by vacuum distillation
and the residue thus obtained was treated with 200 mL of 10%
sodium carbonate solution. Thus, the solid product obtained
was ﬁltered, washed with distilled water and dried at 60 C.
The white product was obtained after recrystallization using
75 mL of 95% ethanol solution. The product was then taken
in 500 mL round bottom ﬂask containing 200 mL of 50%
HCl solution. The mixture was then reﬂuxed until the clear
solution was obtained. The resulting solution was cooled
and basiﬁed with 10% NaOH solution. The precipitated prod-
uct was ﬁltered and washed with distilled water. It was recrys-
tallized using 75 mL of 95% ethanol.
3.3. General procedure for the diazotization of sulfonamide
substituted 4-(3H)-quinazolinone derivatives
Diazotization of compounds 8a–8j was carried out by the re-
ported method (Jeffery et al., 1989). Accordingly, a solution
of compounds 8a–8j (0.01 mol) in 3 mL concentrated HCl
was cooled to 0–5 C in ice bath. The cooled sodium nitrite
solution (1.5 g. in 10 mL of water) was added to it dropwise
for 10 min. The reaction mixture was then stirred for 30 min.
to produce diazotized compounds (Scheme 3). The reaction
mass was stored at 0–5 C and was directly used for the next
step.
3.4. General procedure for the preparation of hydrazono
derivatives 9a–9j
Compounds 9a–9j were prepared using an ice-cold mixture of
the active methylene compound (acetyl acetone) (0.01 mol)
and sodium acetate (0.05 mol) in ethanol (50 mL) was added
dropwise with stirring to a solution of diazotized compounds
8a–8j over a period of 15 min. The stirring was continued for
30 min. and the reaction mixture was then left for 2 h. at room
temperature, and the progress of reaction was monitored by
TLC (9:0.5, CHCl3:MeOH solvent system). The solid yellow
product thus obtained was ﬁltered, washed with cold water
and recrystallized from ethanol to give the corresponding
hydrazono derivatives 9a–9j.
3.4.1. 4-[N0-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(2-
methyl-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide (9a)
Yellow crystals (61%), m.p. 167–168 C, Anal. Calcd. For
C20H19N5O5S: C, 54.41; H, 4.34; N, 15.86%. Found: C,
54.55; H, 4.42; N, 15. 69%. IR (KBr, cm1): 3056 (aromatic
CAH stretching), 2863 (aliphatic CAH stretching), 1695
(C‚O stretching), 1601 (aromatic C‚C stretching), 1510
(aromatic NAH bending), 1550 (NAH bending of SO2NH
group), 1450 (aliphatic CAH bending), 1324, 1142 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.91 (s, 1H), 9.11 (s, 1H), 7.75 (dd, J= 7.91,
1.46 Hz, 1H), 7.69 (td, J= 12.06, 1.48 Hz, 1H), 7.55 (dd,J= 7.96, 1.40 Hz, 1H), 7.36 (td, J= 7.16, 1.40 Hz, 1H),
7.11 (dd, J= 8.67, 2.61 Hz, 2H), 6.53 (dd, J= 9.71,
2.15 Hz, 2H), 2.51 (s, 6H), 2.25 (s, 3H). 13C NMR
(100 MHz, DMSO-d6): d 190.0, 188.1, 158.6, 157.3, 153.1,
146.5, 135.4, 130.2, 127.1, 126.8, 123.7, 121.0, 113.0, 28.8,
23.1. MS (ESI) (m/z): 442.2 [M+H]+.
3.4.2. 4-[N0-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(6-
bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide
(9b)
Yellow crystals (62%), m.p. 145–147 C, Anal. Calcd. For
C20H18BrN5O5S: C, 46.16; H, 3.49; N, 13.46%. Found: C,
46.34; H, 3.58; N, 13.60%. IR (KBr, cm1): 3073 (aromatic
CAH stretching), 2864 (aliphatic CAH stretching), 1697
(C‚O stretching), 1601 (aromatic C‚C stretching), 1512
(aromatic NAH bending), 1556 (NAH bending of SO2NH
group), 1451 (aliphatic CAH bending), 1322, 1139 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.79 (s, 1H), 9.21 (s, 1H), 8.42 (d,
J= 2.21 Hz, 1H), 7.70 (d, J= 10.45 Hz, 1H), 7.59 (dd,
J= 10.49, 2.17 Hz, 1H), 7.35 (dd, J= 8.64, 2.62 Hz, 2H),
6.46 (dd, J= 8.72, 2.13 Hz, 2H), 2.49 (s, 6H), 2.31 (s, 3H).
13C NMR (100 MHz, DMSO-d6): d 192.5, 191.1, 162.2,
158.1, 152.6, 147.9, 137.2, 131.3, 125.3, 124.2, 126.6, 126.1,
123.8, 121.9, 113.1, 27.9, 25.8, 24.1. MS (ESI) (m/z): 520.1,
522.3 [M]+.
3.4.3. 4-[N0-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(6,8-
dibromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-
benzenesulfonamide (9c)
Yellow crystals (65%), m.p. 172–174 C, Anal. Calcd. For
C20H17Br2N5O5S: C, 40.09; H, 2.86; N, 11.69%. Found: C
40.18, H 2.98, N 11.80%. IR (KBr, cm1): 3062 (aromatic
CAH stretching), 2855 (aliphatic CAH stretching), 1696
(C‚O stretching), 1602 (aromatic C‚C stretching), 1511
(aromatic NAH bending), 1553 (NAH bending of SO2NH
group), 1453 (aliphatic CAH bending), 1323, 1141 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.82 (s, 1H), 9.21 (s, 1H), 8.47 (d,
J= 2.38 Hz, 1H), 8.08 (d, J= 2.35 Hz, 1H), 7.40 (dd,
J= 8.67, 2.61 Hz, 2H), 6.57 (dd, J= 10.72, 2.54 Hz, 2H),
2.48 (s, 6H), 2.28 (s, 3H). 13C NMR (100 MHz, DMSO-d6):
d 191.6, 184.1, 166.2, 162.3, 151.7, 151.6, 137.9, 132.6, 130.3,
129.1, 126.2, 124.4, 118.4, 114.1, 114.1, 26.8. MS (ESI) (m/z):
597.2, 599.1, 601.3 [M]+.
3.4.4. 4-(2-(2,4-dioxopentan-3-ylidene)hydrazinyl)-N-(6-nitro-
4-oxo-2-phenylquinazolin-3(4H)-yl)benzenesulfonamide (9d)
Yellow crystals (61%), m.p. 189–190 C, Anal. Calcd. For
C25H20N6O7S: C, 54.74; H, 3.68; N, 15.32%. Found: C,
54.49; H, 3.76; N, 15.22%. IR (KBr, cm1): 3058 (aromatic
CAH stretching), 2858 (aliphatic CAH stretching), 1694
(C‚O stretching), 1602 (aromatic C‚C stretching), 1510
(aromatic NAH bending), 1552 (NAH bending of SO2NH
group), 1456 (aliphatic CAH bending), 1321, 1143 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.88 (s, 1H), 9.14 (s, 1H), 6.9–8.6 (m, 12H),
2.47 (s, 6H). 13C NMR (100 MHz, DMSO-d6): d 198.3,
161.4, 153.7, 152.2, 146.6, 132.0, 131.4, 130.2, 130.1, 129.1,
128.7, 128.3, 128.1, 125.5, 123.6, 123.0, 121.9, 116.8, 26.9.
MS (ESI) (m/z): 549.4 [M+H]+.
S34 N.A. Sojitra et al.3.4.5. 4-[N0-(1-Acetyl-2-oxopropylidene)hydrazino]-N-(4-oxo-
2-phenyl-4H-quinazolin-3-yl)benzenesulfonamide (9e)
Yellow crystals (64%), m.p. 164–166 C, Anal. Calcd. For
C25H21N5O5S: C, 59.63; H, 4.20; N, 13.91%. Found: C,
59.54; H, 4.40; N, 13.99%. IR (KBr, cm1): 3071 (aromatic
CAH stretching), 2891 (aliphatic CAH stretching), 1698
(C‚O stretching), 1608 (aromatic C‚C stretching), 1501
(aromatic NAH bending), 1560 (NAH bending of SO2NH
group), 1462 (aliphatic CAH bending), 1326, 1135 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.88 (s, 1H), 9.20 (s, 1H), 6.5–8.2 (m, 13H),
2.53 (s, 6H). 13C NMR (100 MHz, DMSO-d6): d 195.6,
191.1, 161.9, 153.6, 151.5, 147.5, 136.2, 132.8, 133.6, 132.5,
128.7, 126.9, 126.8, 126.1, 125.0, 124.8, 123.6, 121.6, 114.3,
27.7, 25.9. MS (ESI) (m/z): 504.2 [M+H]+.
3.4.6. 4-[N0-(1-Acetyl-2-oxopropylidene)hydrazino]-N-(6-
bromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)benzenesulfonamide
(9f)
Yellow crystals (65%), m.p. 183–184 C, Anal. Calcd. For
C25H20BrN5O5S: C, 51.55; H, 3.46; N, 12.02%. Found: C,
51.64; H, 3.53; N, 12.07%. IR (KBr, cm1): 3068 (aromatic
CAH stretching), 2882 (aliphatic CAH stretching), 1694
(C‚O stretching), 1602 (aromatic C‚C stretching), 1498
(aromatic NAH bending), 1550 (NAH bending of SO2NH
group), 1450 (aliphatic CAH bending), 1321, 1136 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.91 (s, 1H), 9.10 (s, 1H), 6.5–8.4 (m, 12H),
2.49 (s, 6H). 13C NMR (100 MHz, DMSO-d6): d 198.6,
194.1, 165.4, 153.6, 152.6, 147.6, 138.6, 132.9, 131.7, 130.8,
130.0, 129.6, 127.1, 126.3, 126.0, 124.6, 122.7, 115.8, 115.1,
28.8, 26.0. MS (ESI) (m/z): 582.3, 584.4 [M]+.
3.4.7. 4-[N0-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(6,8-
dibromo-4-oxo-2-phenyl-4H-quinazolin-3-
yl)benzenesulfonamide (9g)
Yellow crystals (61%), m.p. 193–195 C, Anal. Calcd. For
C25H19Br2N5O5S: C, 45.40; H, 2.90; N, 10.59%. Found: C,
45.45; H, 2.99; N, 10.68%. IR (KBr, cm1): 3067 (aromatic
CAH stretching), 2858 (aliphatic CAH stretching), 1694
(C‚O stretching), 1601 (aromatic C‚C stretching), 1503
(aromatic NAH bending), 1551 (NAH bending of SO2NH
group), 1452 (aliphatic CAH bending), 1326, 1141 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.86 (s, 1H), 9.13 (s, 1H), 6.6–8.5 (m, 11H),
2.53 (s, 6H). 13C NMR (100 MHz, DMSO-d6): d 178.6,
174.1, 163.9, 159.6, 153.1, 152.8, 138.4, 134.7, 133.7, 131.5,
129.9, 129.7, 127.3, 126.0, 125.1, 124.4, 119.0, 114.1, 111.0,
27.9, 25.9. MS (ESI) (m/z): 660.0, 662.2, 663.9 [M]+.
3.4.8. 4-[N0-(1-Acetyl-2-oxopropylidene)hydrazino]-N-[2- (4-
chlorophenyl)-4-oxo-4H-quinazolin-3-yl]benzenesulfonamide
(9h)
Yellow crystals (65%), m.p. 178–180 C, Anal. Calcd. For
C25H20ClN5O5S: C, 55.81; H, 3.75; N, 13.02%. Found: C,
55.83; H, 3.83; N, 13.11%. IR (KBr, cm1): 3077 (aromatic
CAH stretching), 2861 (aliphatic CAH stretching), 1693
(C‚O stretching), 1602 (aromatic C‚C stretching), 15012
(aromatic NAH bending), 1555 (NAH bending of SO2NH
group), 1446 (aliphatic CAH bending), 1325, 1145 (asymmet-ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.84 (s, 1H), 9.09 (s, 1H), 6.6–8.1 (m, 12H),
2.49 (s, 6H). 13C NMR (100 MHz, DMSO-d6): d 197.3,
187.3, 165.9, 154.8, 148.4, 135.9, 134.2, 132.9, 130.2, 129.4,
128.1, 127.8, 127.5, 126.0, 125.4, 124.6, 123.8, 113.2, 28.8,
25.1. MS (ESI) (m/z): 538.0, 539.8 [M]+.
3.4.9. 4-[N0-(1-Acetyl-2-oxopropylidene)hydrazino]-N-[6-
bromo-2-(4-chlorophenyl)-4-oxo-4H-quinazolin-3-
yl]benzenesulfonamide (9i)
Yellow crystals (64%), m.p. 203–204 C, Anal. Calcd. For
C25H19BrClN5O5S: C, 48.68; H, 3.10; N, 11.35%. Found: C
48.56, H 3.04, N 11.27%. IR (KBr, cm1): 3069 (aromatic
CAH stretching), 2873 (aliphatic CAH stretching), 1698
(C‚O stretching), 1600 (aromatic C‚C stretching), 1504
(aromatic NAH bending), 1551 (NAH bending of SO2NH
group), 1449 (aliphatic CAH bending), 1322, 1140 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.81 (s, 1H), 9.16 (s, 1H), 6.6–8.2 (m, 11H),
2.49 (s, 6H). 13C NMR (100 MHz, DMSO-d6): d 193.4,
191.6, 158.4, 153.7, 152.5, 149.3, 138.6, 137.9, 133.6, 133.0,
131.0, 129.8, 129.5, 128.2, 126.2, 125.8, 124.6, 123.1, 115.7,
113.1, 29.8, 25.7. MS (ESI) (m/z): 616.2, 617.9, 620.0 [M]+.
3.4.10. 4-[N0-(1-Acetyl-2-oxopropylidene)hydrazino]-N-[6,8-
dibromo-2-(4-chlorophenyl)-4-oxo-4H-quinazolin-3-
yl]benzenesulfonamide (9j)
Yellow crystals (65%), m.p. 214–215 C, Anal. Calcd. For
C25H18Br2ClN5O5S: C, 43.16; H, 2.61; N, 10.07%. Found:
C, 43.02; H, 2.50; N, 10.01%. IR (KBr, cm1): 3052 (aromatic
CAH stretching), 2868 (aliphatic CAH stretching), 1692
(C‚O stretching), 1601 (aromatic C‚C stretching), 1509
(aromatic NAH bending), 1556 (NAH bending of SO2NH
group), 1453 (aliphatic CAH bending), 1328, 1142 (asymmet-
ric and symmetric S‚O stretching). 1H NMR (400 MHz,
DMSO-d6): d 10.83 (s, 1H), 9.17 (s, 1H), 8.46 (d,
J= 2.38 Hz, 1H), 8.11 (d, J= 2.38 Hz, 1H), 7.92 (dd,
J= 8.23, 2.77 Hz, 2H), 7.48 (dd, J= 8.21, 2.70 Hz, 2H),
7.35 (dd, J= 8.26, 2.81 Hz, 2H), 6.54 (dd, J= 10.12,
2.63 Hz, 2H), 2.46 (s, 6H). 13C NMR (100 MHz, DMSO-d6):
d 191.4, 177.5, 162.9, 161.4, 153.3, 152.8, 138.3, 137.6, 134.6,
133.3, 131.9, 130.4, 130.7, 126.1, 125.9, 123.8, 123.7, 118.5,
115.1, 112.0, 32.8, 24.7. MS (ESI) (m/z): 693.8, 695.7, 697.7,
699.9 [M]+.
3.5. General cyclization procedure for the preparation of
pyrazole substituted quinazolinone derivatives 10a–10j
It was prepared using the solution of the appropriate hydazon-
o compounds 9a–9j (0.01 mol) in 30 ml of glacial acetic acid
added with phenyl hydrazine (0.012 mol) and anhydrous so-
dium acetate (0.01 mol). The reaction mixture was heated un-
der reﬂux subsequently for 4–8 h. After completion of reaction
(checked by TLC using 9:0.5, CHCl3:CH3OH solvent system),
the mixture was poured into ice-cold water and stored in a
refrigerator until the product separated out. The crude prod-
uct, was ﬁltered, washed with water, dried and recrystallized
from methanol. The colors of the compounds were yellowish
orange to orange and are soluble in polar organic solvents like
methanol, ethanol and pyridine.
Classical and microwave assisted synthesis S353.5.1. 4-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylazo)-N-(2-
methyl-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide (10a)
Orange crystals (73%), m.p. 189–190 C, Anal. Calcd. For
C26H23N7O3S: C, 60.81; H, 4.51; N, 19.09%. Found: C,
60.93; H, 4.65; N, 19.22%. IR (KBr, cm1): 3050 (aromatic
CAH stretching), 2862 (aliphatic CAH stretching), 1697
(C‚O stretching), 1601 (aromatic C‚C stretching), 1580
(N‚N stretching), 1554 (NAH bending of SO2NH group),
1453 (aliphatic CAH bending), 1324, 1142 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-
d6): d 10.80 (s, 1H), 6.8–7.9 (m, 13H) 2.87 (s, 3H), 2.44 (s,
3H), 2.30 (s, 3H). 13C NMR (100 MHz, DMSO-d6): d 158.3,
156.5, 153.2, 151.9, 146.8, 146.1, 144.0, 139.1, 135.4, 130.2,
128.6, 127.1, 126.8, 126.0, 123.7, 121.0, 119.6, 113.0, 22.5,
12.2, 10.3. MS (ESI) (m/z): 514.2 [M+H]+.
3.5.2. N-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-4-(3,5-
dimethyl-1-phenyl-1H-pyrazol-4-ylazo)benzenesulfonamide (10b)
Orange crystals (76%), m.p. 195–196 C, Anal. Calcd. For
C26H22BrN7O3S: C, 52.71; H, 3.74; N, 16.55%. Found: C,
52.89; H, 3.86; N, 16.72%. IR (KBr, cm1): 3068 (aromatic
CAH stretching), 2857 (aliphatic CAH stretching), 1693
(C‚O stretching), 1602 (aromatic C‚C stretching), 1573
(N‚N stretching), 1550 (NAH bending of SO2NH group),
1455 (aliphatic CAH bending), 1322, 1140 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-
d6): d 10.83 (s, 1H), 6.8–8.3 (m, 12H) 2.77(s, 3H), 2.57 (s,
3H), 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6): d 162.3,
158.5, 152.2, 150.4, 148.7, 147.6, 142.9, 138.3, 136.1, 133.2,
128.4, 127.6, 127.3, 127.2, 126.7, 125.2, 122.3, 117.5, 116.2,
24.0, 13.1, 10.1. MS (ESI) (m/z): 592.2, 594.1 [M]+.
3.5.3. N-(6,8-Dibromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-4-
(3,5-dimethyl-1-phenyl-1H-pyrazol-4-
ylazo)benzenesulfonamide (10c)
Orange crystals (83%), m.p. 174–176 C, Anal. Calcd. For
C26H21Br2N7O3S: C, 46.51; H, 3.15; N, 14.60%. Found: C,
46.63; H, 3.24; N, 14.74%. IR (KBr, cm1): 3061 (aromatic
CAH stretching), 2876 (aliphatic CAH stretching), 1694
(C‚O stretching), 1601 (aromatic C‚C stretching), 1576
(N‚N stretching), 1553 (NAH bending of SO2NH group),
1460 (aliphatic CAH bending), 1319, 1138 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-
d6): d 10.77 (s, 1H), 7.1–8.5 (m, 11H) 2.83 (s, 3H), 2.51 (s,
3H), 2.35 (s, 3H). 13C NMR (100 MHz, DMSO-d6): d 165.1,
163.4, 153.2, 152.4, 151.3, 145.5, 145.0, 141.2, 139.6, 133.6,
131.2, 129.6, 127.0, 125.8, 123.2, 121.3, 117.3, 113.4, 24.1,
11.7, 11.1. MS (ESI) (m/z): 670.2, 672.3, 674.2 [M]+.
3.5.4. 4-((3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)diazenyl)-N-
(6-nitro-4-oxo-2-phenylquinazolin-3(4H)-
yl)benzenesulfonamide (10d)
Yellowish-orange crystals (78%), m.p. 224–225 C, Anal.
Calcd. For C31H24N8O5S: C, 59.99; H, 3.90; N, 18.05%. Found:
C, 60.12; H, 3.74; N, 17.97%. IR (KBr, cm1): 3064 (aromatic
CAH stretching), 2852 (aliphatic CAH stretching), 1697
(C‚O stretching), 1603 (aromatic C‚C stretching), 1578
(N‚N stretching), 1550 (NAH bending of SO2NH group),
1450 (aliphatic CAH bending), 1324, 1144 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-d6):
d 10.91 (s, 1H), 7.2–8.7 (m, 17H) 2.47 (s, 3H), 2.32 (s, 3H). 13CNMR (100 MHz, DMSO-d6): d 162.5, 158.7, 155.5, 151.8,
145.2, 140.1, 139.4, 137.9, 132.3, 130.8, 129.7, 129.2, 128.7,
128.3, 128.0, 127.3, 126.7, 125.9, 125.5, 124.9, 124.5, 122.3,
110.5, 19.2, 11.7. MS (ESI) (m/z): 620.9 [M+H]+.
3.5.5. 4-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylazo)-N-(4-
oxo-2-phenyl-4H-quinazolin-3-yl)benzenesulfonamide (10e)
Orange crystals (81%), m.p. 241–243 C, Anal. Calcd. For
C31H25N7O3S: C, 64.68; H, 4.38; N, 17.03%. Found: C, 64.86;
H, 4.54; N, 17.18%. IR (KBr, cm1): 3077 (aromatic CAH
stretching), 2865 (aliphatic CAH stretching), 1694 (C‚O
stretching), 1602 (aromatic C‚C stretching), 1578 (N‚N
stretching), 1556 (NAH bending of SO2NH group), 1454 (ali-
phatic CAH bending), 1323, 1144 (asymmetric and symmetric
S‚O stretching). 1H NMR (400 MHz, DMSO-d6): d 10.88 (s,
1H), 6.8–8.2 (m, 18H), 2.52 (s, 3H), 2.41 (s, 3H). 13C NMR
(100 MHz, DMSO-d6): d 163.7, 152.5, 152.3,151.2, 148.8,
137.4, 131.5, 130.6, 130.2, 129.6, 127.7, 145.6, 143.1, 138.2,
126.6, 126.5, 126.1, 125.9, 125.0, 124.4, 121.5, 117.2, 116.3,
11.8, 10.5. MS (ESI) (m/z): 576.1 [M+H]+.
3.5.6. N-(6-Bromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)-4-(3,5-
dimethyl-1-phenyl-1H-pyrazol-4-ylazo)benzenesulfonamide
(10f)
Orange crystals (71%), m.p. 167–168 C, Anal. Calcd. For
C31H24BrN7O3S: C, 56.88; H, 3.70; N, 14.98%. Found: C,
56.97; H, 3.79; N, 14.76%. IR (KBr, cm1): 3061 (aromatic
CAH stretching), 2855 (aliphatic CAH stretching), 1695
(C‚O stretching), 1601 (aromatic C‚C stretching), 1571
(N‚N stretching), 1556 (NAH bending of SO2NH group),
1452 (aliphatic CAH bending), 1323, 1137 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-
d6): d 10.92 (s, 1H), 6.6–8.4 (m, 17H), 2.51 (s, 3H), 2.45 (s,
3H). 13C NMR (100 MHz, DMSO-d6): d 161.3, 154.5, 153.6,
148.8, 147.3, 145.5, 142.4, 138.3, 137.3, 135.1, 134.1, 131.7,
130.3, 129.4, 129.0, 128.4, 127.1, 124.8, 122.6, 121.6, 121.2,
118.7, 116.45, 11.78, 11.02. MS (ESI) (m/z): 654.2, 656.1 [M]+.
3.5.7. N-(6,8-Dibromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)-4-
(3,5-dimethyl-1-phenyl-1H-pyrazol-4-
ylazo)benzenesulfonamide (10g)
Orange crystals (78%), m.p. 199–201 C, Anal. Calcd. For
C31H23Br2N7O3S: C, 50.77; H, 3.16; N, 13.37%. Found: C,
50.87; H, 3.21; N 13.46%. IR (KBr, cm1): 3057 (aromatic
CAH stretching), 2850 (aliphatic CAH stretching), 1696
(C‚O stretching), 1604 (aromatic C‚C stretching), 1581
(N‚N stretching), 1553 (NAH bending of SO2NH group),
1450 (aliphatic CAH bending), 1325, 1141 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-d6):
d 10.85 (s, 1H), 6.5–8.4 (m, 16H), 2.46 (s, 3H), 2.39 (s, 3H).
13C NMR (100 MHz, DMSO-d6): d 162.8, 160.4, 158.5, 155.3,
152.8, 147.6, 146.8, 139.8, 138.4, 134.6, 133.7, 132.7, 130.3,
128.2, 127.6, 127.2, 125.5, 125.2, 124.3, 121.5, 117.2, 115.4,
110.1, 13.1, 11.1. MS (ESI) (m/z): 732.1, 734.1, 735.8 [M]+.
3.5.8. N-[2-(4-Chlorophenyl)-4-oxo-4H-quinazolin-3-yl]-4-
(3,5-dimethyl-1-phenyl-1H-pyrazol-4-
ylazo)benzenesulfonamide (10h)
Orange crystals (73%), m.p. 241–243 C, Anal. Calcd. For
C31H24ClN7O3S: C, 61.03; H, 3.97; N, 16.07%. Found: C,
S36 N.A. Sojitra et al.61.14; H, 3.86; N, 16.13%. IR (KBr, cm1): 3058 (aromatic
CAH stretching), 2863 (aliphatic CAH stretching), 1695
(C‚O stretching), 1601 (aromatic C‚C stretching), 1574
(N‚N stretching), 1557 (NAH bending of SO2NH group),
1455 (aliphatic CAH bending), 1326, 1142 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-d6):
d 10.77 (s, 1H), 6.5–8.3 (m, 17H), 2.52 (s, 3H), 2.43 (s, 3H).
13C NMR (100 MHz, DMSO-d6): d 162.4, 154.5, 153.6, 152.4,
148.3, 145.4, 143.2, 137.7, 137.1, 135.4, 132.6, 131.7, 129.6,
128.2, 127.7, 127.1, 126.8, 126.0, 125.8, 125.5, 123.4, 122.6,
120.8, 114.1, 13.1, 10.1. MS (ESI) (m/z): 610.2, 612.3 [M]+.
3.5.9. N-[6-Bromo-2-(4-chlorophenyl)-4-oxo-4H-quinazolin-3-
yl]-4-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-
ylazo)benzenesulfonamide (10i)
Orange crystals (78%), m.p. 231–233 C, Anal. Calcd. For
C31H23BrClN7O3S: C, 54.04; H, 3.36; N, 14.23%. Found: C,
54.38; H, 3.46; N, 14.42%. IR (KBr, cm1): 3057 (aromatic
CAH stretching), 2850 (aliphatic CAH stretching), 1697
(C‚O stretching), 1602 (aromatic C‚C stretching), 1579
(N‚N stretching), 1550 (NAH bending of SO2NH group),
1454 (aliphatic CAH bending), 1324, 1141 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-
d6): d 10.79 (s, 1H), 6.6–8.4 (m, 16H), 2.47 (s, 3H), 2.35
(s, 3H). 13C NMR (100 MHz, DMSO-d6): d 161.4, 154.5,
153.2, 149.3, 147.8, 147.2, 143.2, 137.8, 137.1, 135.3, 134.8,
134.0, 132.1, 130.5, 129.3, 127.4, 126.9, 126.2, 125.7, 124.6,
123.5, 118.8, 118.0, 113.3, 11.8, 11.0. MS (ESI) (m/z): 688.2,
690.3, 692.1 [M]+.
3.5.10. N-[6,8-Dibromo-2-(4-chlorophenyl)-4-oxo-4H-
quinazolin-3-yl]-4-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-
ylazo)benzenesulfonamide (10j)
Orange crystals (73%), m.p. 219–220 C, Anal. Calcd. For
C31H22Br2ClN7O3S: C, 48.49; H, 2.89; N, 12.77%. Found:
C, 48.64; H, 2.99; N, 12.83%. IR (KBr, cm1): 3078 (aromatic
CAH stretching), 2861 (aliphatic CAH stretching), 1696
(C‚O stretching), 1603 (aromatic C‚C stretching), 1581
(N‚N stretching), 1557 (NAH bending of SO2NH group),
1451 (aliphatic CAH bending), 1323, 1139 (asymmetric and
symmetric S‚O stretching). 1H NMR (400 MHz, DMSO-
d6): d 10.83 (s, 1H), 6.5–8.5 (m, 15H), 2.51 (s, 3H), 2.39
(s, 3H). 13C NMR (100 MHz, DMSO-d6): d 162.6, 158.5,
153.3, 152.7, 152.4, 147.8, 142.3,139.3, 138.5, 138.2, 134.1,
133.5, 132.6, 131.4, 130.7, 129.9, 128.5, 127.1, 125.5, 124.7,
117.6, 118.6, 118.2, 110.8, 13.2, 10.7. MS (ESI) (m/z): 766.1,
767.9, 779.8, 782.2 [M]+.
3.6. In vitro antimicrobial studies
The in vitro antimicrobial activities of all the synthesized com-
pounds were screened for their antibacterial activity against S.
aureus, Bacillus subtilis (Gram Positive) and E. coli, P. aerugin-
osa (Gram Negative), whereas of antifungal against A. niger
and A. clavatus using the broth dilution method (Jani et al.,
2010). All the ATCC cultures were collected from the Institute
of Microbial Technology, Bangalore. 2% Luria broth solution
was prepared in distilled water while, pH of the solution was
adjusted to 7.4 ± 0.2 at room temperature and sterilized by
autoclaving at 15 lb pressure for 25 min. The tested bacterial
and fungal strains were prepared in the luria broth andincubated at 37 C and 200 rpm in an orbital incubator for
overnight. Sample solutions were prepared in DMSO for var-
ious concentrations at 250, 200, 150, 100, 50, 25 and 10 lg/mL.
The standard drug solution of Streptomycin (antibacterial
drug) and Nystatin (antifungal drug) was prepared in DMSO.
Serial broth micro dilution was adopted as a reference method.
10 ll solution of test compound was inoculated in 5 mL luria
broth for each concentrations respectively and additionally
one test tube was kept as control. Each of the test tubes was
inoculated with a suspension of standard microorganism to
be tested and incubated at 35 C for 24 h. At the end of the
incubation period, the tubes were examined for turbidity. Tur-
bidity in the test tubes indicated that microorganism growth
was not inhibited by the antibiotic contained in the medium
at the test concentration. The antimicrobial activity tests were
performed in triplicate and the deviation for any triplicate re-
sults was not more than ±1–5% while average MIC values of
the compounds are summarized in Table 2.
4. Conclusion
In extension to our earlier work newer 4-(3,5-dimethyl-1-phe-
nyl-1H-pyrazol-4-ylazo)-N-(2-substituted-4-oxo-4H-quinazo-
lin-3-yl)benzenesulfonamide derivatives 10a–10j were
synthesized via classical and microwave irradiation. Micro-
wave irradiations have been veriﬁed more preferable over con-
ventional heating. The in vitro study of all the new compounds
possesses moderate to excellent antimicrobial activity against
bacteria but poor for fungal compared to bacteria.Acknowledgments
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